Nevro Corp. is relying on compelling clinical data to drive adoption of its Senza line of spinal cord stimulation systems delivering its proprietary HFX (high-frequency) 10 kHz spinal cord stimulation therapy.
The US Food and Drug Administration approved the original version of Senza in 2015 based on results of the SENZA RCT trial, which showed HFX therapy provides long-term improvements...